NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types
The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases
https://finance.yahoo.com/news/nurix-therapeutics-awarded-innovation-passport-200100697.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.